Macrophage Membrane-coated Nanocarriers Co-Modified by RVG29 and TPP Improve Brain Neuronal Mitochondria-targeting and Therapeutic Efficacy in Alzheimer's Disease Mice

Overview

Journal Bioact Mater

Specialty Biomedical Engineering

Date 2020 Sep 30

PMID 32995678

Citations 51

Authors

Yang Han

Chunhong Gao

Hao Wang

Jiejie Sun

Meng Liang

Ye Feng

Qianqian Liu

Shiyao Fu

Lin Cui

Chunsheng Gao

Yi Li

Yang Yang

Baoshan Sun

Affiliations

Soon will be listed here.

Abstract

Neuronal mitochondrial dysfunction caused by excessive reactive oxygen species (ROS) is an early event of sporadic Alzheimer's disease (AD), and considered to be a key pathologic factor in the progression of AD. The targeted delivery of the antioxidants to mitochondria of injured neurons in brain is a promising therapeutic strategy for AD. A safe and effective drug delivery system (DDS) which is able to cross the blood-brain barrier (BBB) and target neuronal mitochondria is necessary. Recently, bioactive materials-based DDS has been widely investigated for the treatment of AD. Herein, we developed macrophage (MA) membrane-coated solid lipid nanoparticles (SLNs) by attaching rabies virus glycoprotein (RVG29) and triphenylphosphine cation (TPP) molecules to the surface of MA membrane (RVG/TPP-MASLNs) for functional antioxidant delivery to neuronal mitochondria. According to the results, MA membranes camouflaged the SLNs from being eliminated by RES-rich organs by inheriting the immunological characteristics of macrophages. The unique properties of the DDS after decoration with RVG29 on the surface was demonstrated by the ability to cross the BBB and the selective targeting to neurons. After entering the neurons in CNS, TPP further lead the DDS to mitochondria driven by electric charge. The Genistein (GS)- encapsulated DDS (RVG/TPP-MASLNs-GS) exhibited the most favorable effects on reliveing AD symptoms and by the synergies gained from the combination of MA membranes, RVG29 and TPP. These results demonstrated a promising therapeutic candidate for delaying the progression of AD via neuronal mitochondria-targeted delivery by the designed biomimetic nanosystems.

Citing Articles

Mitochondria-targeted nanovesicles for ursodeoxycholic acid delivery to combat neurodegeneration by ameliorating mitochondrial dysfunction.

Zhang S, Li M, Li Y, Yang S, Wang J, Ren X J Nanobiotechnology. 2025; 23(1):202.

PMID: 40069803 PMC: 11895296. DOI: 10.1186/s12951-025-03258-5.

Pathway-based network medicine identifies novel natural products for Alzheimer's disease.

Liang Y, Xie S, Jia J Alzheimers Res Ther. 2025; 17(1):43.

PMID: 39953559 PMC: 11829514. DOI: 10.1186/s13195-025-01694-x.

Nanoscale drug formulations for the treatment of Alzheimer's disease progression.

Liu L, He H, Du B, He Y RSC Adv. 2025; 15(6):4031-4078.

PMID: 39926227 PMC: 11803502. DOI: 10.1039/d4ra08128e.

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

Mitochondrial dysfunction in Alzheimer's disease: a key frontier for future targeted therapies.

Wang S, Liao Z, Zhang Q, Han X, Liu C, Wang J Front Immunol. 2025; 15:1484373.

PMID: 39877373 PMC: 11772192. DOI: 10.3389/fimmu.2024.1484373.

References

Verdin E, Hirschey M, Finley L, Haigis M . Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010; 35(12):669-75. PMC: 2992946. DOI: 10.1016/j.tibs.2010.07.003. View

Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T . Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015; 18(11):1584-93. PMC: 4694577. DOI: 10.1038/nn.4132. View

Kohara Y, Kawaguchi S, Kuwahara R, Uchida Y, Oku Y, Yamashita K . Genistein improves spatial learning and memory in male rats with elevated glucose level during memory consolidation. Physiol Behav. 2014; 140:15-22. DOI: 10.1016/j.physbeh.2014.12.005. View

Soucy N, Parkinson H, Sochaski M, Borghoff S . Kinetics of genistein and its conjugated metabolites in pregnant Sprague-Dawley rats following single and repeated genistein administration. Toxicol Sci. 2005; 90(1):230-40. DOI: 10.1093/toxsci/kfj077. View

Swerdlow R, Khan S . A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses. 2004; 63(1):8-20. DOI: 10.1016/j.mehy.2003.12.045. View

Biswas S, Dodwadkar N, Deshpande P, Torchilin V . Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release. 2012; 159(3):393-402. PMC: 3348446. DOI: 10.1016/j.jconrel.2012.01.009. View

Du H, Guo L, Yan S, Sosunov A, McKhann G, Yan S . Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A. 2010; 107(43):18670-5. PMC: 2972922. DOI: 10.1073/pnas.1006586107. View

Swerdlow R . Mitochondria and Mitochondrial Cascades in Alzheimer's Disease. J Alzheimers Dis. 2017; 62(3):1403-1416. PMC: 5869994. DOI: 10.3233/JAD-170585. View

Park T, Singh B, Li H, Lee J, Kang S, Choi Y . Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease. Biomaterials. 2014; 38:61-71. DOI: 10.1016/j.biomaterials.2014.10.068. View

10.

Cui G, Guo H, Li H, Zhai Y, Gong Z, Wu J . RVG-modified exosomes derived from mesenchymal stem cells rescue memory deficits by regulating inflammatory responses in a mouse model of Alzheimer's disease. Immun Ageing. 2019; 16:10. PMC: 6515654. DOI: 10.1186/s12979-019-0150-2. View

11.

Brynskikh A, Zhao Y, Mosley R, Li S, Boska M, Klyachko N . Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond). 2010; 5(3):379-96. PMC: 2880389. DOI: 10.2217/nnm.10.7. View

12.

Selfridge J, E L, Lu J, Swerdlow R . Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol Dis. 2012; 51:3-12. PMC: 3337963. DOI: 10.1016/j.nbd.2011.12.057. View

13.

Cao H, Dan Z, He X, Zhang Z, Yu H, Yin Q . Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer. ACS Nano. 2016; 10(8):7738-48. DOI: 10.1021/acsnano.6b03148. View

14.

Wang J, Chen G . Mitochondria as a therapeutic target in Alzheimer's disease. Genes Dis. 2018; 3(3):220-227. PMC: 6150105. DOI: 10.1016/j.gendis.2016.05.001. View

15.

Zhang T, Wang H, Ye Y, Zhang X, Wu B . Micellar emulsions composed of mPEG-PCL/MCT as novel nanocarriers for systemic delivery of genistein: a comparative study with micelles. Int J Nanomedicine. 2015; 10:6175-84. PMC: 4598212. DOI: 10.2147/IJN.S91348. View

16.

Fu S, Liang M, Wang Y, Cui L, Gao C, Chu X . Dual-Modified Novel Biomimetic Nanocarriers Improve Targeting and Therapeutic Efficacy in Glioma. ACS Appl Mater Interfaces. 2018; 11(2):1841-1854. DOI: 10.1021/acsami.8b18664. View

17.

Ma J, Zhang S, Liu J, Liu F, Du F, Li M . Targeted Drug Delivery to Stroke via Chemotactic Recruitment of Nanoparticles Coated with Membrane of Engineered Neural Stem Cells. Small. 2019; 15(35):e1902011. PMC: 11089900. DOI: 10.1002/smll.201902011. View

18.

Zhou S, Hu Y, Zhang B, Teng Z, Gan H, Yang Z . Dose-dependent absorption, metabolism, and excretion of genistein in rats. J Agric Food Chem. 2008; 56(18):8354-9. DOI: 10.1021/jf801051d. View

19.

Zhang Y, Cai K, Li C, Guo Q, Chen Q, He X . Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy. Nano Lett. 2018; 18(3):1908-1915. PMC: 7470025. DOI: 10.1021/acs.nanolett.7b05263. View

20.

Baer G, Shaddock J, Quirion R, Dam T, Lentz T . Rabies susceptibility and acetylcholine receptor. Lancet. 1990; 335(8690):664-5. DOI: 10.1016/0140-6736(90)90454-d. View